← Назад

Facioscapulohumeral dystrophy

ORPHA:269DiseaseAutosomal dominantAll ages

Ассоциированные гены (6)

DNMT3B
DNA methyltransferase 3 beta
Modifying germline mutation in
OMIM: 602900
DUX4
double homeobox 4
Candidate gene tested in
OMIM: 606009
DUX4L1
double homeobox 4 like 1 (pseudogene)
Candidate gene tested in
FRG1
FSHD region gene 1
Candidate gene tested in
OMIM: 601278
SMCHD1
structural maintenance of chromosomes flexible hinge domain containing 1
Disease-causing germline mutation(s) in
OMIM: 614982
SMCHD1
structural maintenance of chromosomes flexible hinge domain containing 1
Modifying germline mutation in
OMIM: 614982

Фенотипы (37)

Очень частый (80–99%)6
HP:0000298Mask-like facies
HP:0003202Skeletal muscle atrophy
HP:0003236Elevated circulating creatine kinase concentration
HP:0003307Hyperlordosis
HP:0003323Progressive muscle weakness
HP:0003691Scapular winging
Частый (30–79%)25
HP:0000407Sensorineural hearing impairment
HP:0000491Keratitis
HP:0000509Conjunctivitis
HP:0000767Pectus excavatum
HP:0001288Gait disturbance
HP:0001538Protuberant abdomen
HP:0002091Restrictive ventilatory defect
HP:0002359Frequent falls
HP:0002650Scoliosis
HP:0003325Limb-girdle muscle weakness
HP:0003376Steppage gait
HP:0003458EMG: myopathic abnormalities
HP:0004673Decreased facial expression
HP:0006587Straight clavicles
HP:0008046Abnormal retinal vascular morphology
HP:0008959Distal upper limb muscle weakness
HP:0009023Abdominal wall muscle weakness
HP:0009027Foot dorsiflexor weakness
HP:0011712Right bundle branch block
HP:0012037Pectoralis amyotrophy
HP:0012532Chronic pain
HP:0030002Nocturnal lagophthalmos
HP:0030319Weakness of facial musculature
HP:0030664Beevor's sign
HP:0100595Camptocormia
Периодический (5–29%)6
HP:0000541Retinal detachment
HP:0000572Visual loss
HP:0001250Seizure
HP:0002093Respiratory insufficiency
HP:0005115Supraventricular arrhythmia
HP:0007898Exudative retinopathy

Эпидемиология (6)

Point prevalence
1-9 / 100 000
Europe
Point prevalence
1-9 / 100 000
Italy
Point prevalence
1-9 / 100 000
United Kingdom
Point prevalence
1-9 / 100 000
Japan
Point prevalence
1-5 / 10 000
Netherlands
Annual incidence
1-9 / 1 000 000
Netherlands

Лекарства и терапия

Источник: Open Targets Platform (в реальном времени)

Клинические исследования

Источник: ClinicalTrials.gov (в реальном времени)

Внешние ресурсы